Sirtris Pharma Says SRT501 Slows Retinal Ganglion Cell Loss During Optic Neuritis - Quick Facts

Tue. March 04, 2008; Posted: 08:25 AM

(RTTNews) - Sirtris Pharmaceuticals, Inc. (SIRT | news | PowerRating | PR Charts ) revealed that its SRT501, when orally administered, slows retinal ganglion cell loss during optic neuritis, which is a neurodegenerative eye disorder, and also suppresses neurological dysfunction in a preclinical model of Multiple Sclerosis.

The pharmaceutical company noted that Kenneth Shindler of the University of Pennsylvania Scheie Eye Institute in Philadelphia would present these results, at the preclinical data at the North American Neuro-Ophthalmology Society annual meeting on March 10, 2008.

For full details for SIRT click here.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.